Currently, the only drugs that radically cure Plasmodium vivax malaria are 8-aminoquinoline–based drugs, which can cause hemolysis in G6PD-deficient patients. Therefore, determination of G6PD level is critical before treatment. This study evaluated tests for G6PD deficiency, including validating the correlation of quantitative reference assays, and establishing recombinant G6PD controls.